These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 34322651)

  • 21. Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing.
    Balmaña J; Digiovanni L; Gaddam P; Walsh MF; Joseph V; Stadler ZK; Nathanson KL; Garber JE; Couch FJ; Offit K; Robson ME; Domchek SM
    J Clin Oncol; 2016 Dec; 34(34):4071-4078. PubMed ID: 27621404
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Multigene Panel Testing on Surgical Decision Making in Breast Cancer Patients.
    Pederson HJ; Gopalakrishnan D; Noss R; Yanda C; Eng C; Grobmyer SR
    J Am Coll Surg; 2018 Apr; 226(4):560-565. PubMed ID: 29360614
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reinterpretation of BRCA1 and BRCA2 variants of uncertain significance in patients with hereditary breast/ovarian cancer using the ACMG/AMP 2015 guidelines.
    So MK; Jeong TD; Lim W; Moon BI; Paik NS; Kim SC; Huh J
    Breast Cancer; 2019 Jul; 26(4):510-519. PubMed ID: 30725392
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinician-Reported Impact of Germline Multigene Panel Testing on Cancer Risk Management Recommendations.
    Horton C; Blanco K; Lo MT; Speare V; LaDuca H; Dolinsky JS; Kurian AW
    JNCI Cancer Spectr; 2022 Mar; 6(2):. PubMed ID: 35603838
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Understanding and interpretation of a variant of uncertain significance (VUS) genetic test result by pediatric providers who do not specialize in genetics.
    Menke C; Nagaraj CB; Dawson B; He H; Tawde S; Wakefield EG
    J Genet Couns; 2021 Dec; 30(6):1559-1569. PubMed ID: 33969574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results.
    Pritzlaff M; Summerour P; McFarland R; Li S; Reineke P; Dolinsky JS; Goldgar DE; Shimelis H; Couch FJ; Chao EC; LaDuca H
    Breast Cancer Res Treat; 2017 Feb; 161(3):575-586. PubMed ID: 28008555
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ethnic disparities among men with prostate cancer undergoing germline testing.
    Kwon DH; Borno HT; Cheng HH; Zhou AY; Small EJ
    Urol Oncol; 2020 Mar; 38(3):80.e1-80.e7. PubMed ID: 31630993
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Next step in molecular genetics of hereditary breast/ovarian cancer: Multigene panel testing in clinical actionably genes and prioritization algorithms in the study of variants of uncertain significance.
    Castillo-Guardiola V; Rosado-Jiménez L; Sarabia-Meseguer MD; Marín-Vera M; Macías-Cerrolaza JA; García-Hernández R; Zafra-Poves M; Sánchez-Henarejos P; Moreno-Locubiche MÁ; Cuevas-Tortosa E; Arnaldos-Carrillo M; Ayala de la Peña F; Alonso-Romero JL; Noguera-Velasco JA; Ruiz-Espejo F
    Eur J Med Genet; 2022 Apr; 65(4):104468. PubMed ID: 35245693
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased yield of actionable mutations using multi-gene panels to assess hereditary cancer susceptibility in an ethnically diverse clinical cohort.
    Ricker C; Culver JO; Lowstuter K; Sturgeon D; Sturgeon JD; Chanock CR; Gauderman WJ; McDonnell KJ; Idos GE; Gruber SB
    Cancer Genet; 2016 Apr; 209(4):130-7. PubMed ID: 26908360
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Uptake and acceptability of a mainstreaming model of hereditary cancer multigene panel testing among patients with ovarian, pancreatic, and prostate cancer.
    Hamilton JG; Symecko H; Spielman K; Breen K; Mueller R; Catchings A; Trottier M; Salo-Mullen EE; Shah I; Arutyunova A; Batson M; Gebert R; Pundock S; Schofield E; Offit K; Stadler ZK; Cadoo K; Carlo MI; Narayan V; Reiss KA; Robson ME; Domchek SM
    Genet Med; 2021 Nov; 23(11):2105-2113. PubMed ID: 34257420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SMA Identified: Clinical and Molecular Findings From a Sponsored Testing Program for Spinal Muscular Atrophy in More Than 2,000 Individuals.
    Bowen BM; Truty R; Aradhya S; Bristow SL; Johnson BA; Morales A; Tan CA; Westbrook MJ; Winder TL; Chavez JC
    Front Neurol; 2021; 12():663911. PubMed ID: 34025568
    [No Abstract]   [Full Text] [Related]  

  • 33. Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients.
    Rodríguez-Balada M; Roig B; Melé M; Albacar C; Serrano S; Salvat M; Querol M; Borràs J; Martorell L; Gumà J
    Clin Biochem; 2020 Feb; 76():17-23. PubMed ID: 31786208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psychosocial problems in women attending French, German and Spanish genetics clinics before and after targeted or multigene testing results: an observational prospective study.
    Brédart A; Kop JL; Dick J; Cano A; De Pauw A; Anota A; Brunet J; Devilee P; Stoppa-Lyonnet D; Schmutzler R; Dolbeault S
    BMJ Open; 2019 Sep; 9(9):e029926. PubMed ID: 31551380
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome.
    Yurgelun MB; Allen B; Kaldate RR; Bowles KR; Judkins T; Kaushik P; Roa BB; Wenstrup RJ; Hartman AR; Syngal S
    Gastroenterology; 2015 Sep; 149(3):604-13.e20. PubMed ID: 25980754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Classification of variants of uncertain significance in BRCA1 and BRCA2 using personal and family history of cancer from individuals in a large hereditary cancer multigene panel testing cohort.
    Li H; LaDuca H; Pesaran T; Chao EC; Dolinsky JS; Parsons M; Spurdle AB; Polley EC; Shimelis H; Hart SN; Hu C; Couch FJ; Goldgar DE
    Genet Med; 2020 Apr; 22(4):701-708. PubMed ID: 31853058
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characteristics of Germline Non-BRCA Mutation Status of High-Risk Breast Cancer Patients in China and Correlation with High-Risk Factors and Multigene Testing Suggestions.
    Su Y; Yao Q; Xu Y; Yu C; Zhang J; Wang Q; Li J; Shi D; Yu B; Zeng Y; Zhu X; Bai Q; Zhou X
    Front Genet; 2021; 12():674094. PubMed ID: 34917121
    [No Abstract]   [Full Text] [Related]  

  • 38. Variants of uncertain significance (VUS) in cancer predisposing genes: What are we learning from multigene panels?
    Lucci-Cordisco E; Amenta S; Panfili A; Del Valle J; Capellá G; Pineda M; Genuardi M
    Eur J Med Genet; 2022 Jan; 65(1):104400. PubMed ID: 34813939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Profiling Oncogenic Germline Mutations in Unselected Chinese Lung Cancer Patients.
    Yang J; Li H; Li B; Li W; Guo Q; Hu L; Song Z; Zhou B
    Front Oncol; 2021; 11():647598. PubMed ID: 33898318
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic testing for hereditary gastrointestinal cancer syndromes: Interpreting results in today's practice.
    Powers JM; Ebrahimzadeh JE; Katona BW
    Curr Treat Options Gastroenterol; 2019 Dec; 17(4):636-649. PubMed ID: 31761969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.